[go: up one dir, main page]

WO2015154254A1 - Gender specific synthetic nutritional compositions and nutritional systems comprising them - Google Patents

Gender specific synthetic nutritional compositions and nutritional systems comprising them Download PDF

Info

Publication number
WO2015154254A1
WO2015154254A1 PCT/CN2014/074993 CN2014074993W WO2015154254A1 WO 2015154254 A1 WO2015154254 A1 WO 2015154254A1 CN 2014074993 W CN2014074993 W CN 2014074993W WO 2015154254 A1 WO2015154254 A1 WO 2015154254A1
Authority
WO
WIPO (PCT)
Prior art keywords
age
infant
gender specific
methionine
gender
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2014/074993
Other languages
French (fr)
Inventor
Michael Affolter
Sagar THAKKAR
Carlos Antonio DE CASTRO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestle China Ltd
Original Assignee
Nestle China Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestle China Ltd filed Critical Nestle China Ltd
Priority to PCT/CN2014/074993 priority Critical patent/WO2015154254A1/en
Priority to CN201580018797.0A priority patent/CN106455659A/en
Priority to AU2015245728A priority patent/AU2015245728A1/en
Priority to AU2015101939A priority patent/AU2015101939A4/en
Priority to RU2016143871A priority patent/RU2704227C2/en
Priority to MX2016012555A priority patent/MX389070B/en
Priority to RU2019132115A priority patent/RU2019132115A/en
Priority to EP15776825.0A priority patent/EP3131416A4/en
Priority to PCT/CN2015/076032 priority patent/WO2015154659A1/en
Priority to US15/302,735 priority patent/US20170035088A1/en
Publication of WO2015154254A1 publication Critical patent/WO2015154254A1/en
Priority to PH12016501919A priority patent/PH12016501919B1/en
Anticipated expiration legal-status Critical
Priority to US16/544,297 priority patent/US20200054062A1/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/20Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A23C9/206Colostrum; Human milk
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/19Dairy proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients

Definitions

  • the concentration of methionine in the gender specific synthetic nutritional compositions of the invention,and nutritional systems comprising them more accurately reflect the concentration of methionine found in HM produced for infants of the same gender and age.
  • HM is considered optimal with respect to infant nutrition,they can provide an optimized amount of methionine to an infant of4to8months,1to2months of age,and up to 1month of age,more particularly2weeks to1month of age.
  • the gender specific synthetic nutritional composition is selected from the group consisting of:infant formula and a composition for infants that is intended to be added or diluted to human milk e.g.HM fortifier.
  • the term“gender specific synthetic nutritional composition”as used herein refers to any synthetic nutritional composition,intended to be consumed by an infant that is specifically adapted to the nutritional needs of either a female or male ieri.
  • infant refers to a human infant of12months of age or less.
  • the gender specific synthetic nutritional composition can be a male specific synthetic nutritional composition or a female specific synthetic nutritional composition.
  • the gender specific synthetic nutritional composition is a male specific synthetic nutritional composition for an infant of4to8months of age and comprises methionine in a concentration of4.2mg to31.2mg,12.19mg to13.73mg,or13.73mg,per100g.
  • the gender specific synthetic nutritional composition is a female specific synthetic nutritional composition for an infant of up to1month,more particularly2weeks to1 month,of age and comprises methionine in a concentration of9.7mg to28.3mg,9.7mg to17mg, or16.67mg,per100g.
  • the methionine may be intact,hydrolysed,partially hydrolysed,or any combination thereof.
  • Non limiting examples of carbohydrates include lactose,saccharose,maltodexirin,starch,and combinationsthereof.
  • prebiotics include:oligosaccharides optionally containing fructose, galactose,mannose;dietary fibers,in particular soluble fibers,soy fibers;inulin;and combinations thereof.
  • Preferred prebiotics are fructo-oligosaccharides(FOS),galacto- oligosaccharides(GOS),isomalto-oligosaccharides(IMO),xylo-oligosaccharides(XOS),arabino- xylo oligosaccharides(AXOS),mannan-oligosaccharides(MOS),oligosaccharides of soy, glycosylsucrose(GS),lactosucrose(LS),lactulose(LA),palatinose-oligosaccharides(PAO),malto- oligosaccharides,gums and/or hydrolysates thereof,pectins and/or hydrolysates thereof,and combinations of the foregoing.
  • FOS fruct
  • oligosaccharide is described in Wrodnigg,T.M.;Stutz,A.E.(1999)Angew. Chem.Int.Ed.38:827-828and in WO2012/069416which is incorporated herein by reference.
  • vitamins and minerals include:vitamin A,vitamin B1,vitamin B2, vitamin B6,vitamin Bi2,vitamin E.vitamin K.vitamin C,vitamin D,folic acid,inositol,niacin, biotin,pantothenic acid,choline,calcium,phosphorous,iodine,iron,magnesium,copper,zinc, manganese,chloride,potassium,sodium,selenium,chromium,molybdenum,taurine,L- carnitine,and combinations thereof.Minerals are usually added in salt form.
  • compositions of the invention may be prepared by methods well known in the art for preparing that type of synthetic nutritional composition e.g.infant formulae,follow on formulae,a composition for infants that is intended to be added or diluted with HM e.g.HM fortifier,and food stuffs intended for consumption by infants either alone or in combination with HM e.g.complementary foods.
  • synthetic nutritional composition e.g.infant formulae,follow on formulae,a composition for infants that is intended to be added or diluted with HM e.g.HM fortifier,and food stuffs intended for consumption by infants either alone or in combination with HM e.g.complementary foods.
  • the liquid mixture may then be thermally treated to reduce bacterial loads.
  • the liquid mixture may be rapidly heated to a temperature in the range of about80°Cto about1 10°Cfor about5seconds to about5minutes.This may be carried out by steam injection or by heat exchanger;for example a plate heat exchanger.
  • the liquid mixture may then be cooled to about60°Cto about85°C;for example by flash cooling.
  • the liquid mixture may then be homogenised;for example in two stages at about7MPa to about40MPa in the first stage and about2MPa to about14MPa in the second stage.
  • the homogenised mixture may then be further cooled to add any heat sensitive components such as vitamins and minerals.
  • the pH and solids content of the homogenised mixture is conveniently standardised at this point.
  • the homogenised mixture can be transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
  • a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
  • the powder should have a moisture content of less than about3%by weight.
  • probiotic(s) can be added, they may be cultured according to any suitable method and prepared for addition to the infant formula by freeze-drying or spray-drying for example.
  • bacteria preparations can be bought from specialist suppliers such as Christian Hansen and Morinaga already prepared in a suitable form for addition to food products such as infant formula.Such bacterial preparations may be added to the gender specific powdered infant formula by dry mixing.
  • the gender specific compositions of the invention may also be prepared from a gender neutral synthetic nutritional composition in a method comprising;measuring out an appropriate amount of said gender neutral synthetic nutritional composition and mixing it with an additive and/or diluent e.g.water so as to arrive at a gender specific nutritional composition in accordancewiththeinvention.
  • the additive may be a gender specific additive comprising caseins in a particular concentration so that when mixed with the gender neutral synthetic nutritional composition,and optionally a diluent,the resulting mixture is a gender specific synthetic nutritional composition of the invention.
  • One or more of the gender specific synthetic nutritional compositions of the invention can be included in a nutritional system.
  • the term“nutritional system”as used herein refers to a collection of more than one synthetic nutritional composition advertised or sold as part of the same product range e.g. a collection of infant formulas sold under the same brand and adapted to the nutritional needs of infants of differing genders and/or ages.
  • the synthetic nutritional compositions making up the nutritional system may be packaged individually e.g.in capsules or boxes.Said packages can be sold individually,grouped together e.g.wrapped by plastic film or combined in a box,or in a combination of these two ways.
  • the nutritional system may comprise only gender specific synthetic nutritional compositions,or it may comprise a mix of gender specific and gender neutral synthetic nutritional compositions.
  • gender neutral as used herein is synonymous with unisex.
  • a nutritional system comprising at least one of the gender specific synthetic nutritional compositions of the invention.
  • the nutritional system comprises at least one gender specific synthetic nutritional composition for a male infant and at least one gender specific nutritional composition for a female infant wherein,said male and female gender specific synthetic nutritional compositions are for infants of the same age selected from the group consisting of:4 to8months of age,1to2months of age,up to1month of age,more particularly2weeks to1 month of age.
  • the gender specific synthetic nutritional compositions are for infants of4to8months of age and up to1month of age,more particularly2weeks to1month of age,and the concentration of methionine in said male gender specific synthetic nutritional composition is higher than that of said female gender specific synthetic nutritional composition.
  • the concentration of methionine in the male gender synthetic nutritional compositions may be higher by any amount.
  • the ratio of the concentration of methionine between the female gender specific nutritional composition and male gender specific synthetic nutritional composition for infants of4months to8months of age is1:62.4to1:1.015,1:62.4to1:1.2;or1:8.4to1:1.43, and/or the male gender specific nutritional composition comprises30.7mg to0.001mg,30.7mg to3.08mg,or9.5mg to3.7mg more methionine per100g than the female gender specific nutritional composition.
  • the ratio of the concentration of methionine between the female gender specific nutritional composition and male gender specific synthetic nutritional composition for infants of up to1month of age,more particularly2weeks to1month of age,is1:5.2to1:1.055, 1:5.2to1:1.1;or1:1.75to1:1.15,and/or the male gender specific nutritional composition comprises40mg to0.0001mg,40mg to2.54mg,or21.4mg to2.54mg more methionine per 100g than the female gender specific nutritional composition.
  • the gender specific synthetic nutritional compositions are for infants of1to2months of age and the concentration of methionine in said male gender specific synthetic nutritional composition is lower than that of said female gender specific synthetic nutritional composition.
  • the concentration of methionine in the male gender synthetic nutritional compositions may be lower by any amount.
  • the nutritional system comprises male and female gender specific synthetic nutritional compositions for infants1to2months of age wherein,the ratio of the methionine concentration between the female gender specific nutritional composition and male gender specific synthetic nutritional composition is1:0.8to1:0.98,or1:0.8to1:0.5,and/or the female gender specific nutritional composition comprises3.6mg to0.001mg,or3.6mg to2mg more methionine per100g than the male gender specific nutritional composition.
  • the nutritional system further comprises gender specific synthetic nutritional compositions for infants of up to2weeks of age and/or2months to4months of age wherein,the concentration of methionine does not differ by gender for infants of the same age.
  • the nutritional system further comprises gender neutral specific synthetic nutritional compositions for infants up to2weeks of age and/or2months to4months of age.
  • the nutritional system may further comprise nutritional compositions for infants older than8 months of age and children older than12months.
  • a gender specific synthetic nutritional composition and/or nutrition system according to the invention is particularly suitable for use in a method of preparing single servings of infant formula using capsules,each capsule of which contains a unit dose of a synthetic nutritional composition in concentrated form,and which is equipped with opening means contained within the capsule to permit draining of the reconstituted synthetic nutritional composition directly from the capsule into a receiving vessel such as a baby bottle.Such a method is described in WO2006/077259.
  • the different synthetic nutritional compositions including gender specific and gender neutral synthetic nutritional compositions,which may be comprised within a nutrition system,may be packed into individual capsules and presented to the consumer in multipacks containing a sufficient number of capsules to meet the requirements of an infant of a particular age or age range,for one week for example.
  • suitable capsule constructions are disclosed in WO2003/059778.
  • the capsules can contain the synthetic nutritional compositions,(gender specific and gender neutral)in the form of powders or concentrated liquids in both cases for reconstitution by an appropriate amount of water.Both the composition and the quantity of infant formula in the capsules may vary according to the gender and/or age of the infant.If necessary,different sizes of capsules may be provided for the preparation of infant formulas for infants of different genders and/or ages.
  • the gender specific synthetic nutritional compositions,or nutritional systems comprising them better reflect the differences in the concentration of methionine found in HM depending on the gender of the mother’s infant at one or more stages of lactation.As stated herein,optimum methionine intake helps to ensure the optimum growth and development of an infant..
  • a gender specific synthetic nutritional composition may provide an optimum amount of total methionine,to an infant4to8months of age,1to2months of age,or up to1month of age, more particularly2weeks to1month of age.
  • the nutritional system may provide an optimum amount of total methionine,to an infant up to 12months of age,up to9months of age,up to8months of age,up to6months of age,up to1 month of age.
  • a method for providing an optimum amount of methionineto an infant of4to8months of age,1to2months of age,or up to1 month of age,more particularly2weeks to1month of age comprising:
  • the gender specific synthetic nutritional compositions may be prepared from gender neutral synthetic nutritional compositions.
  • a kit for providing an optimized amount of total methionineto an infant of4to8months of age,1to2months of age,or up to1month of age,more particularly 2weeks to1month of age comprising:
  • the dosage requirements may be with respect to the quantity of the gender neutral synthetic nutritional employed and/or consumption frequency e.g.4times per day.
  • Subjects included in the survey referenced herein were recruited from4provinces across China. Accordingly,the gender specific synthetic nutritional compositions and/or nutritional systems disclosed herein can be particularly relevant for Chinese infants,and or infants born in populations having common genetic origins and/or ethnic origins and/or common dietary habits thereto e.g.Asian,Indian,and/or Mongoloid populations.
  • HM samples were collected as part of a cross sectional survey of HM. The study criteria is set out below:
  • compositional analysis was then subject to a statistical analysis employing the following statistical model:
  • the following table shows the estimates for gender differences per timeframe along with the corresponding Pvalues.
  • a P-value inferior to0.1for a particular timeframe suggests that there is a statistically significant difference in the concentration of methionine in HM produced for males and females infants at that specific timeframe.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pediatric Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dairy Products (AREA)

Abstract

Gender specific synthetic nutritional compositions for infants 4 to 8 months of age, 1 to 2 months of age, or up to 1 month of age wherein, the concentration of methionine is adapted based on that found in HM produced for an infant of the same gender and age, and nutritional systems comprising them.

Description

无标题
Title:Gender specific synthetic nutritional compositions and nutritional systems comprising  them.
Technical field:The invention relates to gender specific synthetic nutritional compositions, to  nutritional systems comprising them and, to their use to provide optimised nutrition and/or one  ormorehealthbenefittoaninfant.
Background of the invention
Even though breastfeeding is optimal for infants, existence of certain conditions may not be in  the best interests of the infant and it may contraindicate breastfeeding (AAP, 2012; Lawrence, 2013). In such cases, where the sole source of nutrition is not available to the infant, alternative  strategies to feed them have to be devised. Feeding infants with Synthetic nutritional  compositions e.g. Infant formula is one such strategy.
The compositions of the aforementioned synthetic nutritional compositions are modeled on  those of human milk. However, the composition of HM is extremely dynamic and these dynamic  changes remain largely unexplored and uncharacterized. Whilst it is known that components  and/or their quantities may vary depending on a variety of factors including the stage of  lactation, circadian rhythms and even gender, it is not known which of the numerous  components vary and if so how they vary e.g. by stage of lactation and/or gender.
Surprisingly it has now been identifiedthat 4 to 8 months, 1 to 2 months, and up to 1 month, more particularly 2 weeks to 1 month, postpartum, there is a difference in the methionine  concentration range found in HM produced by mother’s to girls in comparison to mother’s to  boys . This finding stems from a cross-sectional study of HM wherein, HM samples from  mothers to either boys or girls were collected at various stages postpartum and analysed. Further, it was also surprisingly found that 4 to 8 months and up to 1 month, more particularly 2 weeks to 1 month, postpartum the methionine concentration in HM produced by mothers to  boys was higher than that produced for mothers to girls. Conversely, it was also surprisingly  found that 1 to 2 months postpartum the methionine concentration in HM produced by  mothers to boys was lower than that produced for mothers to girls  Because these gender differences in the concentration of methionine in HM have never been  previously identified,they are not reflected in the compositions of synthetic nutritional  compositions available today.
Methionine is an amino acids.An optimum intake of amino acids helps to ensure optimum  growth and development in infants.
Optimum growth and development may be immediate and/or long term.Long term may only  be evident in months or years e.g.6months,9months,12months,5years,10years,or20 years.
Accordingly,there remains a need for gender specific synthetic nutritional compositions,and  nutritional systems comprising them,having compositions within which the identified gender  differences,with respect to concentration ranges of methionine,found in HM4to8months,1 to2months,and up to1month,more particularly2weeks to1month,postpartum are more  accurately reflected and thereby optimised.
Summary of the invention
The invention is set out in the claims.The inventors have found that the concentration ranges  of methionine in HM varies4to8months,1to2months,and up to1month,more particularly  2weeks to1month,postpartum depending on the gender of the mother’s infant.In light of this  finding the inventors have developed gender specific nutritional compositions and nutritional  systems comprising them,that reflect these identified gender differences.Prior to  aforementioned findings the skilled person has not incentive to develop such gender specific  synthetic nutritional compositions or to include them in nutritional systems.
The concentration of methionine in the gender specific synthetic nutritional compositions of the  invention,and nutritional systems comprising them,more accurately reflect the concentration  of methionine found in HM produced for infants of the same gender and age.In light of this and, because HM is considered optimal with respect to infant nutrition,they can provide an  optimized amount of methionine to an infant of4to8months,1to2months of age,and up to  1month of age,more particularly2weeks to1month of age.
The gender specific synthetic nutritional compositions can be prepared from a gender neutral  synthetic nutritional composition by measuring out an appropriate amount of said gender  neutral synthetic nutritional composition and mixing it with an additive and/or diluent.
Since optimised methionine intake is helps to ensure the optimum growth and development of  an infant,the gender specific synthetic nutritional compositions,and nutritional systems of the  invention,can also be used to treat,prevent or mitigate sub optimal growth e.g.obesity of an  infant.
Optionally the gender specific synthetic nutritional composition is selected from the group  consisting of:infant formula and a composition for infants that is intended to be added or  diluted to human milk e.g.HM fortifier.
In addition to that set out above,the inventors have also found that the mean concentration of  methionine in HM does not vary by gender2to4months postpartum.In light of this,in addition  to comprising the gender specific synthetic nutritional compositions of the invention,the  nutritional systems disclosed herein may optionally also comprise synthetic nutritional  compositions for infants of2to4months of age wherein,the concentration of methionine does  not differ by gender.Accordingly,the nutritional systems of the invention may provide  optimized nutrition and/or one or more health benefits for an infant up to12months of age,up  to9months of age,up to8months of age,up to6months of age.
Drawings
FIG.1is a graphical representation of the mean concentration of methionine in HM by gender at  up to2weeks(5-11days),2weeks to1month(12-30days),1to2months(31to60days),2to 4months(61to120days),and4to8months(121to240days)postpartum.
Detailed Description
As stated herein,the inventors performed a cross sectional study evaluating the nutrient  composition of HM collected from mothers at various stages of lactation(up to2weeks(5-11 days),2weeks to1month(12-30days),1to2months(31to60days),2to4months(61to120 days),and4to8months(121to240days)postpartum).The study indicated different min and  max ranges for the concentration of ranges of methionine by gender.Surprisingly,the results of  this study also indicated that4to8months,1to2months,and up to1month,more  particularly2weeks to1month,postpartum,there is a difference in the concentration of  methionine in HM depending on the gender of the mother’s infant.Further details of the study, analysis techniques and results are given in example1.
Based on the findings of the study,the inventors have designed gender specific synthetic  nutritional compositions for infants of4to8months,1to2months,up to1month,more  particularly2weeks to1month,of age wherein,the concentration of methionine is adapted  based on that found in HM produced for an infant of the same gender and age.
The term“gender specific synthetic nutritional composition”as used herein refers to any  synthetic nutritional composition,intended to be consumed by an infant that is specifically  adapted to the nutritional needs of either a female or male enfant.
Non limiting examples of gender specific synthetic nutritional compositions for infants from  birth to4months include;infant formulae,and a composition for infants that is intended to be  added or diluted with HM e.g.HM fortifier.Non limiting examples of gender specific synthetic  nutritional compositions for infants from4months to12months include infant formulae,a  composition for infants that is intended to be added or diluted with HM e.g.HM fortifier,or  food stuffs intended for consumption by infants either alone or in combination with HM e.g. complementary foods.
The term“infant”as used herein refers to a human infant of12months of age or less. In a first aspect of the invention there is provided a gender specific synthetic nutritional  composition for an infant of4to8months of age,1to2months of age,up to1month of age, more particularly2weeks to1month of age,wherein,the concentration of methionine is  adapted based on that found in HM produced for an infant of the same gender and age.
The gender specific synthetic nutritional composition can be a male specific synthetic nutritional  composition or a female specific synthetic nutritional composition.
In an embodiment the gender specific synthetic nutritional composition is a female specific  synthetic nutritional composition for an infant of4to8months of age and comprises  methionine in a concentration of0.5mg to12mg,0.5mg to21.7mg,or10.65mg,per100g.
In an embodiment the gender specific synthetic nutritional composition is a male specific  synthetic nutritional composition for an infant of4to8months of age and comprises  methionine in a concentration of4.2mg to31.2mg,12.19mg to13.73mg,or13.73mg,per100g.
In an embodiment the gender specific synthetic nutritional composition is a female specific  synthetic nutritional composition for an infant of up to1month,more particularly2weeks to1 month,of age and comprises methionine in a concentration of9.7mg to28.3mg,9.7mg to17mg, or16.67mg,per100g.
In an embodiment the gender specific synthetic nutritional composition is a male specific  synthetic nutritional composition for an infant of up to1month,more particularly2weeks to1 month,of age and comprises methionine in a concentration of9.6mg to49.7mg,17.95mg to 49.7mg,30.84mg to49.7mg,,19.22mg,per100g.
In an embodiment the gender specific synthetic nutritional composition is a female specific  synthetic nutritional composition for an infant of1to2months of age and comprises  methionine in a concentration of4.8mg to30.2mg,13.29mg to30.2mg or15.05mg,per100g.
In an embodiment the gender specific synthetic nutritional composition is a male specific  synthetic nutritional composition for an infant of1to2months of age and comprises  methionine in a concentration of2.8mg to30.2mg,2.8mg to13mg,or13.73mg,per100g.
The concentration of methionine can be measured by methods well known in the art.In  particular its concentration can be measured by an amino acid analyzer(using post-column  derivatisation with ninhydrin)or by a pre-column derivatisation method(i.e.using PITC or  OPA/FMOC chemistry as described in Blankenship D.T.et al.(1989)Analytical Biochemistry178: 227)followed by HPLC separation and quantification.
Any source of methionine known to be employed in the types of synthetic nutritional  compositions disclosed herein may be comprised within in the gender specific synthetic  nutritional compositions of the invention,in particular pure synthetic methionine obtained  through synthesis or fermentation,or liberated from any food-grade protein source such as  animal or plant proteins through hydrolysis.
The methionine may be intact,hydrolysed,partially hydrolysed,or any combination thereof.
Non limiting examples of such ingredients include:other amino acids,proteins,carbohydrates, oligosaccharides,lipids,prebiotics or probiotics,essential fatty acids,nucleotides,nucleosides, vitamins,minerals and other micronutrients.
Non limiting examples of other amino acids include,lysine,arginine,alanine,histidine, isoleucine,proline,valine,cysteine,glutamine,glutamic acid,glycine,serine,leucine,threonine, tyrosine,phenylalanine,tryptophane,asparagine,aspartic acid,and combinations thereof.
Non limiting examples of proteins include,caseins,alpha-lactalbumin,lactoferrin,serum  albumin,whey,soy protein,rice protein,corn protein,oat protein,barley protein,wheat  protein,rye protein,pea protein,egg protein,sunflower seed protein,potato protein,fish  protein,meat protein,immunoglobins,and combinations thereof.
Non limiting examples of carbohydrates include lactose,saccharose,maltodexirin,starch,and  combinationsthereof.
Non limiting examples of lipids include:palm olein,high oleic sunflower oil,high oleic safflower  oil,canola oil,fish oil,coconut oil,bovine milk fat,and combinations thereof.
Non limiting examples of essential fatty acids include:linoleic acid(LA),α-linolenic acid(ALA) and polyunsaturated fatty acids(PUFAs).The nutritional compositions of the invention may  further contain gangliosides monosialoganglioside-3(GM3)and disialogangliosides3(GD3), phospholipids such as sphingomyelin,phospholipids phosphatidylcholine, phosphatidylethanolamine,phosphatidylinositol,phosphatidylserine,and combinations thereof.
None limiting examples of prebiotics include:oligosaccharides optionally containing fructose, galactose,mannose;dietary fibers,in particular soluble fibers,soy fibers;inulin;and  combinations thereof.Preferred prebiotics are fructo-oligosaccharides(FOS),galacto- oligosaccharides(GOS),isomalto-oligosaccharides(IMO),xylo-oligosaccharides(XOS),arabino- xylo oligosaccharides(AXOS),mannan-oligosaccharides(MOS),oligosaccharides of soy, glycosylsucrose(GS),lactosucrose(LS),lactulose(LA),palatinose-oligosaccharides(PAO),malto- oligosaccharides,gums and/or hydrolysates thereof,pectins and/or hydrolysates thereof,and  combinations of the foregoing.
Further examples of oligosaccharide are described in Wrodnigg,T.M.;Stutz,A.E.(1999)Angew. Chem.Int.Ed.38:827-828and in WO2012/069416which is incorporated herein by reference.
Non limiting examples of probiotics include:Bifidobacterium,Lactobacillus,Lactococcus, Enterococcus,Streptococcus,Kluyveromyces,Saccharoymces,Candida,in particular selected  from the group consisting of Bifidobacterium longum,Bifidobacterium lactis,Bifidobacterium  animalis,Bifidobacterium breve,Bifidobacterium infantis,Bifidobacterium adolescentis, Lactobacillus acidophilus,Lactobacillus casei,Lactobacillus paracasei,Lactobacillus salivarius, Lactobacillus lactis,Lactobacillus rhamnosus,Lactobacillus johnsonii,Lactobacillus plantarum, Lactobacillus salivarius,Lactococcus lactis,Enterococcus faecium,Saccharomyces cerevisiae, Saccharomyces boulardii or mixtures thereof,preferably selected from the group consisting of  Bifidobacterium longum NCC3001(ATCC BAA-999),Bifidobacterium longum NCC2705(CNCM I- 2618),Bifidobacterium longum NCC490(CNCM I-2170),Bifidobacterium lactis NCC2818(CNCM  I-3446),Bifidobacterium breve strain A,Lactobacillus paracasei NCC2461(CNCM I-2116), Lactobacillus johnsonii NCC533(CNCM I-1225),Lactobacillus rhamnosus GG(ATCC53103), Lactobacillus rhamnosus NCC4007(CGMCC1.3724),Enterococcus faecium SF68(NCC2768; NCIMB10415),and combinations thereof.
Non limiting examples of Nucleotides include:cytidine monophosphate(CMP),uridine  monophosphate(UMP),adenosine monophosphate(AMP),guanosine monophosphate(GMP), andcombinationsthereof.
Non limiting examples of vitamins and minerals include:vitamin A,vitamin B1,vitamin B2, vitamin B6,vitamin Bi2,vitamin E.vitamin K.vitamin C,vitamin D,folic acid,inositol,niacin, biotin,pantothenic acid,choline,calcium,phosphorous,iodine,iron,magnesium,copper,zinc, manganese,chloride,potassium,sodium,selenium,chromium,molybdenum,taurine,L- carnitine,and combinations thereof.Minerals are usually added in salt form.
Other suitable and desirable ingredients of synthetic nutritional compositions,that may be  employed in the gender specific nutritional compositions of the invention,are described in  guidelines issued by the Codex Alimentarius with respect to the type of synthetic nutritional  composition in question e.g.Infant formula,HM fortifier,follow on formula,and food stuffs  intended for consumption by infants e.g.complementary foods.
The gender specific compositions of the invention may be prepared by methods well known in  the art for preparing that type of synthetic nutritional composition e.g.infant formulae,follow  on formulae,a composition for infants that is intended to be added or diluted with HM e.g.HM  fortifier,and food stuffs intended for consumption by infants either alone or in combination  with HM e.g.complementary foods.
An exemplary method for preparing a gender specific powdered infant formula is as follows. Amino acids(including methionine)and/or protein source(comprising bound methionine), carbohydrate source,and fat source may be blended together in appropriate proportions. Emulsifiers maybe included in the blend.Vitamins and minerals may be added at this point but  are usually added later to avoid thermal degradation.Any lipophilic vitamins,emulsifiers and  the like may be dissolved into the fat source prior to blending.Water,preferably water which  has been subjected to reverse osmosis,may then be mixed in to form a liquid mixture.
The liquid mixture may then be thermally treated to reduce bacterial loads.For example,the  liquid mixture may be rapidly heated to a temperature in the range of about80℃to about1 10℃for about5seconds to about5minutes.This may be carried out by steam injection or by  heat exchanger;for example a plate heat exchanger.
The liquid mixture may then be cooled to about60℃to about85℃;for example by flash cooling. The liquid mixture may then be homogenised;for example in two stages at about7MPa to  about40MPa in the first stage and about2MPa to about14MPa in the second stage.The  homogenised mixture may then be further cooled to add any heat sensitive components such as  vitamins and minerals.The pH and solids content of the homogenised mixture is conveniently  standardised at this point.
The homogenised mixture can be transferred to a suitable drying apparatus such as a spray  drier or freeze drier and converted to powder.The powder should have a moisture content of  less than about3%by weight.
If it is desired probiotic(s)can be added,they may be cultured according to any suitable method  and prepared for addition to the infant formula by freeze-drying or spray-drying for example. Alternatively,bacterial preparations can be bought from specialist suppliers such as Christian  Hansen and Morinaga already prepared in a suitable form for addition to food products such as  infant formula.Such bacterial preparations may be added to the gender specific powdered  infant formula by dry mixing.
The gender specific compositions of the invention may also be prepared from a gender neutral  synthetic nutritional composition in a method comprising;measuring out an appropriate  amount of said gender neutral synthetic nutritional composition and mixing it with an additive  and/or diluent e.g.water so as to arrive at a gender specific nutritional composition in  accordancewiththeinvention.
The additive may be a gender specific additive comprising caseins in a particular concentration  so that when mixed with the gender neutral synthetic nutritional composition,and optionally a  diluent,the resulting mixture is a gender specific synthetic nutritional composition of the  invention.
The gender neutral synthetic nutritional composition can be prepared by methods well known  in the art.For example,as laid out above for infant formula.
One or more of the gender specific synthetic nutritional compositions of the invention can be  included in a nutritional system.
The term“nutritional system”as used herein refers to a collection of more than one synthetic  nutritional composition advertised or sold as part of the same product range e.g.a collection of  infant formulas sold under the same brand and adapted to the nutritional needs of infants of  differing genders and/or ages.The synthetic nutritional compositions making up the nutritional  system may be packaged individually e.g.in capsules or boxes.Said packages can be sold  individually,grouped together e.g.wrapped by plastic film or combined in a box,or in a  combination of these two ways.
The nutritional system may comprise only gender specific synthetic nutritional compositions,or  it may comprise a mix of gender specific and gender neutral synthetic nutritional compositions. The term“gender neutral”as used herein is synonymous with unisex.
In a further aspect of the present invention there is provided a nutritional system comprising at  least one of the gender specific synthetic nutritional compositions of the invention.
In an embodiment the nutritional system comprises at least one gender specific synthetic  nutritional composition for a male infant and at least one gender specific nutritional  composition for a female infant wherein,said male and female gender specific synthetic  nutritional compositions are for infants of the same age selected from the group consisting of:4 to8months of age,1to2months of age,up to1month of age,more particularly2weeks to1 month of age.
The herein referenced study indicated that the mean concentration of methionine comprised in  HM produced for male infants of4to8months of age and up to1month of age,more  particularly2weeks to1month of age,was higher than that produced for female infants of the  same age.Conversely,the study indicated that mean concentration of methionine comprised in  HM produced for male infants of1to2months of age was equal to or less than that produced  for female infants of the same age.
In an embodiment the gender specific synthetic nutritional compositions,comprised within the  nutritional system,are for infants of4to8months of age and up to1month of age,more  particularly2weeks to1month of age,and the concentration of methionine in said male  gender specific synthetic nutritional composition is higher than that of said female gender  specific synthetic nutritional composition.
The concentration of methionine in the male gender synthetic nutritional compositions may be  higher by any amount.
In an embodiment the ratio of the concentration of methionine between the female gender  specific nutritional composition and male gender specific synthetic nutritional composition for  infants of4months to8months of age is1:62.4to1:1.015,1:62.4to1:1.2;or1:8.4to1:1.43, and/or the male gender specific nutritional composition comprises30.7mg to0.001mg,30.7mg  to3.08mg,or9.5mg to3.7mg more methionine per100g than the female gender specific  nutritional composition.
In an embodiment the ratio of the concentration of methionine between the female gender  specific nutritional composition and male gender specific synthetic nutritional composition for  infants of up to1month of age,more particularly2weeks to1month of age,is1:5.2to1:1.055, 1:5.2to1:1.1;or1:1.75to1:1.15,and/or the male gender specific nutritional composition  comprises40mg to0.0001mg,40mg to2.54mg,or21.4mg to2.54mg more methionine per  100g than the female gender specific nutritional composition.
In another embodiment the gender specific synthetic nutritional compositions,comprised  within the nutritional system,are for infants of1to2months of age and the concentration of  methionine in said male gender specific synthetic nutritional composition is lower than that of  said female gender specific synthetic nutritional composition.
The concentration of methionine in the male gender synthetic nutritional compositions may be  lower by any amount.
In another embodiment the nutritional system comprises male and female gender specific  synthetic nutritional compositions for infants1to2months of age wherein,the ratio of the  methionine concentration between the female gender specific nutritional composition and male  gender specific synthetic nutritional composition is1:0.8to1:0.98,or1:0.8to1:0.5,and/or the  female gender specific nutritional composition comprises3.6mg to0.001mg,or3.6mg to2mg  more methionine per100g than the male gender specific nutritional composition.
In addition to that disclosed hereinabove,the referenced study further indicated that2to4 months,and up to2weeks postpartum there is no difference in the mean concentration of  methionine in HM depending on the gender of the mother’s infant.
In another embodiment the nutritional system further comprises gender specific synthetic  nutritional compositions for infants of up to2weeks of age and/or2months to4months of age  wherein,the concentration of methionine does not differ by gender for infants of the same age.
In another embodiment the nutritional system further comprises gender neutral specific  synthetic nutritional compositions for infants up to2weeks of age and/or2months to4months  of age.
The nutritional system may further comprise nutritional compositions for infants older than8 months of age and children older than12months.
A gender specific synthetic nutritional composition and/or nutrition system according to the  invention is particularly suitable for use in a method of preparing single servings of infant  formula using capsules,each capsule of which contains a unit dose of a synthetic nutritional  composition in concentrated form,and which is equipped with opening means contained within  the capsule to permit draining of the reconstituted synthetic nutritional composition directly  from the capsule into a receiving vessel such as a baby bottle.Such a method is described in  WO2006/077259.
The different synthetic nutritional compositions,including gender specific and gender neutral  synthetic nutritional compositions,which may be comprised within a nutrition system,may be  packed into individual capsules and presented to the consumer in multipacks containing a  sufficient number of capsules to meet the requirements of an infant of a particular age or age  range,for one week for example.Suitable capsule constructions are disclosed in  WO2003/059778.
The capsules can contain the synthetic nutritional compositions,(gender specific and gender  neutral)in the form of powders or concentrated liquids in both cases for reconstitution by an  appropriate amount of water.Both the composition and the quantity of infant formula in the  capsules may vary according to the gender and/or age of the infant.If necessary,different sizes  of capsules may be provided for the preparation of infant formulas for infants of different  genders and/or ages.
The gender specific synthetic nutritional compositions,or nutritional systems comprising them, better reflect the differences in the concentration of methionine found in HM depending on the  gender of the mother’s infant at one or more stages of lactation.As stated herein,optimum  methionine intake helps to ensure the optimum growth and development of an infant..
In another aspect of the present invention there is provided a gender specific synthetic  nutritional composition and/or nutritional system as disclosed herein,for use to treat,prevent  or mitigate sub optimal growth of an infant e.g.obesity
A gender specific synthetic nutritional composition may provide an optimum amount of total  methionine,to an infant4to8months of age,1to2months of age,or up to1month of age, more particularly2weeks to1month of age.
The nutritional system may provide an optimum amount of total methionine,to an infant up to  12months of age,up to9months of age,up to8months of age,up to6months of age,up to1 month of age.
In another aspect of the present invention there is provided a method for providing an optimum  amount of methionineto an infant of4to8months of age,1to2months of age,or up to1 month of age,more particularly2weeks to1month of age comprising:
a)Optionally preparing a gender specific synthetic nutritional compositions according to  the invention from a gender neutral synthetic nutritional composition;
b)Feeding a gender specific synthetic nutritional compositions according to the invention  to an infant of4to8months of age,1to2months of age,or up to1month of age,more  particularly2weeks to1month of age.
As stated herein.The gender specific synthetic nutritional compositions may be prepared from  gender neutral synthetic nutritional compositions.Accordingly,in another aspect of the present  invention there is provided a kit for providing an optimized amount of total methionineto an  infant of4to8months of age,1to2months of age,or up to1month of age,more particularly 2weeks to1month of age,the kit comprising:
a)A gender neutral synthetic nutritional composition
b)A label indicating dosage requirements for an infant so as to arrive at a gender specific  nutritional composition in accordance with the invention.
The dosage requirements may be with respect to the quantity of the gender neutral synthetic  nutritional employed and/or consumption frequency e.g.4times per day.
Subjects included in the survey referenced herein were recruited from4provinces across China. Accordingly,the gender specific synthetic nutritional compositions and/or nutritional systems  disclosed herein can be particularly relevant for Chinese infants,and or infants born in  populations having common genetic origins and/or ethnic origins and/or common dietary habits  thereto e.g.Asian,Indian,and/or Mongoloid populations.
It should be appreciated that all features of the present invention disclosed herein can be freely  combined and that variations and modifications may be made without departing from the scope  of the invention as defined in the claims.Furthermore,where known equivalents exist to  specific features,such equivalents are incorporated as if specifically referred to in this  specification.
There now follows a series of non-limiting examples that serve to illustrate the invention.
Examples
Example1
The concentration of methionine in HM samples collected from mothers to either male or  females was analysed at various stages postpartum.The HM samples were collected as part of a  cross sectional survey of HM.The study criteria is set out below:
Study population
·Number of subjects
Total540healthy subjects were enrolled,allowing a drop-out rate of10percent.They were  comprised of:
–480Lactating mothers in3cities(Beijing,Suzhou and Guangzhou)
–30mothers per city for each of the5time points(5to11days,12to30days,1to2months,2 to4months,and4to8months)
Inclusion/Exclusion criteria
·Inclusion:Healthy Chinese lactating mothers without history of acute and chronic diseases; exclusively breast feeding mothers during4months after delivery were enrolled.
·Exclusion:Chinese lactating mothers having history of psychopathic tendencies and having no dietary memory.
The concentration of methionine in the HM samples collected as part of the above detailed  study were analyzed using firstly acid hydrolysis in6M hydrochloric acid at110℃for22hrs  with phenol antioxidant in the absence of oxygen to liberate all protein-bound methionine, followed secondly by high-sensitivity amino acid analysis using derivatisation with o- Phthalaldehyde(OPA)and9-Fluorenylmethyl Chloroformate(FMOC),and fluorescence  detection(Blankenship D.T.et al.(1989)Analytical Biochemistry178:227).
The results of the compositional analysis of the HM survey,with respect to the concentration of  methionineareshownintableI.
Figure PCTCN2014074993-appb-000001
Table I
The results of the compositional analysis were then subject to a statistical analysis employing  the following statistical model:
Concentration=sex+timeframe+timeframe+sex:timeframe–city+ε
εreferring to the residual error and sex:timeframe referring to the interaction between these2 variables.
The following table shows the estimates for gender differences per timeframe along with the corresponding Pvalues.
The results of the Statistical analysis(statistical inference)are show in in table II.
Figure PCTCN2014074993-appb-000002
Figure PCTCN2014074993-appb-000003
Table II
A P-value inferior to0.1for a particular timeframe suggests that there is a statistically significant  difference in the concentration of methionine in HM produced for males and females infants at  that specific timeframe.
As can be seen from the results in table II,a statistically significant difference in the  concentration of methionine between HM produced for male and female infants was identified  at4to8months,1to2months postpartum,and up to1month postpartum,more specifically 12to30days postpartum.No statistically significant difference was identified in the  concentration of methionine between HM produced for male and female infants2to4months  or less than2weeks(5-11days)postpartum.
Example2
Examples of gender specific infant formulas are given in table III
Figure PCTCN2014074993-appb-000004
Figure PCTCN2014074993-appb-000005
Table III
Example3
An example of a nutritional system in accordance with the invention is given in table IV.
Figure PCTCN2014074993-appb-000006
Figure PCTCN2014074993-appb-000007
Table IV

Claims (18)

  1. A gender specific synthetic nutritional composition for an infant4to8months of age,1 to2months of age,or up to1month of age wherein,the concentration of methionine is  adapted based on that found in human milk produced for an infant of the same gender  and age.
  2. A gender specific synthetic nutritional composition according to claim1wherein,the  concentration of methionine is adapted to an infant of4to8months of age and wherein, if the concentration of methionine is adapted to a male infant it is4.2to31.2,mg per  100g and,if the concentration of methionine is adapted to a female infant it is0.5to 21.7,mg per100g.
  3. A gender specific synthetic nutritional composition according to claim1wherein the  concentration of methionine is adapted to an infant of1to2months of age and wherein, if the concentration of methionine is adapted to a male infant it is2.8to30.2,mg per 100g and,if the concentration of methionine is adapted to a female infant it is4.8to 30.2,mg per L.
  4. A gender specific synthetic nutritional composition according to claim1wherein the  concentration of methionine is adapted to an infant of up to1month of age wherein,if  the concentration of methionine is adapted to a male infant it is9.6to49.7mg per100g  and,if the concentration of methionine is adapted to a female infant it is9.7to28.3mg  per100g.
  5. A composition according to anyone of claims1to4wherein the gender specific synthetic  nutritional composition is selected from the groups consisting of:infant formula,and a  composition for infants that is intended to be added to or diluted with human milk.
  6. A method of preparing a composition as defined in any one of claims1to5comprising: measuring out an appropriate amount of a gender neutral synthetic nutritional  composition and mixing it with an additive and/or diluent.
  7. A nutritional system comprising a gender specific synthetic nutritional composition as  defined in any one of claims1to5.
  8. A nutritional system according to claim7comprising at least one gender specific  synthetic nutritional composition for a male infant as defined in any one of claims1to5 and at least one gender specific nutritional composition for a female infant as defined in  any one of claims1to5wherein,said male and female gender specific synthetic  nutritional compositions are for infants of the same.
  9. A nutritional system according to claim8wherein,if the nutritional system comprises  male and female gender specific synthetic nutritional compositions for infants4to8 months of age as defined in claim1or2,the concentration of methionine in the male  gender specific nutritional composition is higher than that for the female gender specific  synthetic nutritional composition.
  10. A nutritional system according to claim8wherein,if the nutritional system comprises  male and female gender specific synthetic nutritional compositions for infants up to1 month of age as defined in claim1or3,the concentration of methionine in the male  gender specific nutritional composition is higher than that for the female gender specific  synthetic nutritional composition.
  11. A nutritional system according to claim8wherein,if the nutritional system comprises  male and female gender specific synthetic nutritional compositions for infants1to2 months of age as defined in claim1or4,the concentration of methionine in the female  gender specific nutritional composition is higher than that for the male gender specific  synthetic nutritional composition.
  12. A nutritional system according to any one of claims7to11further comprising gender  specific synthetic nutritional compositions for infants of2to4months of age wherein, the concentration of methionine in said gender specific synthetic nutritional  compositions does not differ by gender for infants of the same age.
  13. A nutritional system according to any one of claims7to11further comprising gender  neutral synthetic nutritional compositions for infants of2to4months of age.
  14. Use of a gender specific synthetic nutritional composition as defined in anyone of claims  1to5to provide an optimum amount of methionine to a male or female infant of4to8 months of age,1to2months of age,or up to1month of age.
  15. A gender specific synthetic nutritional composition as defined in anyone of claims1to5 for use to treat,protect or mitigate sub optimal growth and development of an infant.
  16. A method for providing an optimum amount of methionine to an infant of4to8months  of age,1to2months of age,or up to1month of age,comprising:
    a.Optionally preparing a gender specific nutritional compositions as defined in any  one of claims1to5from a gender neutral synthetic nutritional composition;
    b.Feeding a a gender specific nutritional compositions as defined in any one of  claims1to5to an infant of4to8months of age,1to2months of age,or up to1 month of age.
  17. A nutritional system as defined in anyone of claims7to13for use to treat,protect or  mitigate sub optimal growth and development of an infant.
  18. A kit for providing an optimized amount of total methionine to an infant of up to4to8 months age,1to2months of age,or up to1months of age,the kit comprising:
    a.A gender neutral synthetic nutritional composition
    b.A label indicating dosage requirements for an infant so as to arrive at a gender  specific nutritional composition as defined in any one of claims1to5.
PCT/CN2014/074993 2014-04-09 2014-04-09 Gender specific synthetic nutritional compositions and nutritional systems comprising them Ceased WO2015154254A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
PCT/CN2014/074993 WO2015154254A1 (en) 2014-04-09 2014-04-09 Gender specific synthetic nutritional compositions and nutritional systems comprising them
EP15776825.0A EP3131416A4 (en) 2014-04-09 2015-04-08 Gender specific synthetic nutritional compositions and nutritional systems comprising them
PCT/CN2015/076032 WO2015154659A1 (en) 2014-04-09 2015-04-08 Gender specific synthetic nutritional compositions and nutritional systems comprising them
AU2015101939A AU2015101939A4 (en) 2014-04-09 2015-04-08 Gender specific synthetic nutritional compositions and nutritional systems comprising them
RU2016143871A RU2704227C2 (en) 2014-04-09 2015-04-08 Gender specific synthetic nutritional compositions and nutritional systems comprising them
MX2016012555A MX389070B (en) 2014-04-09 2015-04-08 GENDER-SPECIFIC SYNTHETIC NUTRITIONAL COMPOSITIONS AND NUTRITIONAL SYSTEMS THAT COMPRISE THEM.
RU2019132115A RU2019132115A (en) 2014-04-09 2015-04-08 DIFFERENTIATED BY SEX ARTIFICIAL NUTRITION COMPOSITIONS AND CONTAINING THEIR FOOD SYSTEMS
CN201580018797.0A CN106455659A (en) 2014-04-09 2015-04-08 Gender specific synthetic nutritional compositions and nutritional systems comprising them
AU2015245728A AU2015245728A1 (en) 2014-04-09 2015-04-08 Gender specific synthetic nutritional compositions and nutritional systems comprising them
US15/302,735 US20170035088A1 (en) 2014-04-09 2015-04-08 Gender specific synthetic nutritional compositions and nutritional systems comprising them
PH12016501919A PH12016501919B1 (en) 2014-04-09 2016-09-28 Gender specific synthetic nutritional compositions and nutritional systems comprising them
US16/544,297 US20200054062A1 (en) 2014-04-09 2019-08-19 Gender specific synthetic nutritional compositions and nutritional systems comprising them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/074993 WO2015154254A1 (en) 2014-04-09 2014-04-09 Gender specific synthetic nutritional compositions and nutritional systems comprising them

Publications (1)

Publication Number Publication Date
WO2015154254A1 true WO2015154254A1 (en) 2015-10-15

Family

ID=54287098

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2014/074993 Ceased WO2015154254A1 (en) 2014-04-09 2014-04-09 Gender specific synthetic nutritional compositions and nutritional systems comprising them
PCT/CN2015/076032 Ceased WO2015154659A1 (en) 2014-04-09 2015-04-08 Gender specific synthetic nutritional compositions and nutritional systems comprising them

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/076032 Ceased WO2015154659A1 (en) 2014-04-09 2015-04-08 Gender specific synthetic nutritional compositions and nutritional systems comprising them

Country Status (8)

Country Link
US (2) US20170035088A1 (en)
EP (1) EP3131416A4 (en)
CN (1) CN106455659A (en)
AU (2) AU2015101939A4 (en)
MX (1) MX389070B (en)
PH (1) PH12016501919B1 (en)
RU (2) RU2704227C2 (en)
WO (2) WO2015154254A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280788A (en) * 1999-07-01 2001-01-24 葆婴有限公司 Health-care food for baby and its application method
WO2006026879A1 (en) * 2004-09-10 2006-03-16 Medela Holding Ag Method for analysing and treating human milk and system therefore

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132113A (en) * 1990-10-26 1992-07-21 Maurizio Luca Nutritional composition containing essential amino acids
EP1062873A1 (en) * 1999-12-13 2000-12-27 N.V. Nutricia Improved infant formula, protein hydrolysate for use in such an infant formula, and method for producing such a hydrolysate
GB0302929D0 (en) * 2003-02-10 2003-03-12 Inst Of Child Health Nutrient composition
EP1634599A1 (en) * 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
BRPI0519507A2 (en) * 2004-12-27 2009-03-10 Nestec Sa use of reduced protein infant formula
ES2525223T3 (en) * 2006-08-04 2014-12-19 Shs International Ltd. Protein free formula
CN101904362B (en) * 2010-08-10 2013-03-20 河北三元食品有限公司 Soy-based infant powder and preparation method thereof
CN101978841B (en) * 2010-08-31 2013-04-10 浙江贝因美科工贸股份有限公司 Protein allergy-resisting and nutritious infant formula milk powder
EP2452575A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Array of age-tailored nutritional formula with probiotics
CN102551073B (en) * 2012-02-22 2013-11-20 浙江康恩贝健康产品有限公司 Nutritional composition containing alpha-lactoalbumin and lactoferrin and application of nutritional composition
CN103404595B (en) * 2013-07-29 2015-04-15 北安宜品努卡乳业有限公司 Dedicated infant formula for infant boys
EP3079500B1 (en) * 2013-12-12 2019-06-19 Nestec S.A. Synthetic milk compositions for optimal growth and development and prevention of obesity in male and female infant and children

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280788A (en) * 1999-07-01 2001-01-24 葆婴有限公司 Health-care food for baby and its application method
WO2006026879A1 (en) * 2004-09-10 2006-03-16 Medela Holding Ag Method for analysing and treating human milk and system therefore

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALTUFAILY, Y. A. ET AL.: "The effect of infant gender on the quality of breast milk.", KUFA MED. JOURNAL, vol. 1, no. 12, 31 December 2009 (2009-12-31), pages 435 - 440 *
STAM, J. ET AL.: "Can we define an infant's need from the composition of human milk.", THE AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 98, no. 2, 31 December 2013 (2013-12-31), pages 521S - 528S, XP055229603, ISSN: 0002-9165 *
THAKKAR, S. K. ET AL.: "Dynamics of human milk nutrient composition of women from Singapore with a special focus on lipids", AMERICAN JOURNAL OF HUMAN BIOLOGY, vol. 25, no. 6, 31 December 2013 (2013-12-31), pages 770 - 779, XP055229598, ISSN: 1042-0533 *

Also Published As

Publication number Publication date
RU2016143871A3 (en) 2018-10-29
US20170035088A1 (en) 2017-02-09
RU2704227C2 (en) 2019-10-24
PH12016501919A1 (en) 2017-01-09
MX389070B (en) 2025-03-20
AU2015245728A1 (en) 2016-10-06
AU2015245728A2 (en) 2019-01-03
EP3131416A4 (en) 2017-10-04
AU2015101939A6 (en) 2019-01-31
PH12016501919B1 (en) 2017-01-09
EP3131416A1 (en) 2017-02-22
CN106455659A (en) 2017-02-22
WO2015154659A1 (en) 2015-10-15
MX2016012555A (en) 2016-12-14
US20200054062A1 (en) 2020-02-20
RU2019132115A (en) 2019-12-02
RU2016143871A (en) 2018-05-10
AU2015101939A4 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
US20210100273A1 (en) Gender specific synthetic nutritional compositions and nutritional systems comprising them
AU2018102086A4 (en) Gender specific synthetic nutritional compositions and nutritional systems comprising them
AU2018102081A4 (en) Gender specific synthetic nutritional compositions and, nutritional systems comprising them
US20200390139A1 (en) Gender specific synthetic nutritional compositions and nutritional systems comprising them
WO2015154254A1 (en) Gender specific synthetic nutritional compositions and nutritional systems comprising them
US20180279663A1 (en) Gender specific synthetic nutritional compositions and nutritional systems comprising them

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14889090

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14889090

Country of ref document: EP

Kind code of ref document: A1